Semaphore

Sema4 is a health intelligence company that leverages artificial intelligence and machine learning to analyze large-scale genomic and clinical data. Spun out of the Mount Sinai Health System, the company's mission is to provide data-driven insights that improve patient care and accelerate the development of personalized medicine. Its core platform, Centrella, integrates diverse datasets to support diagnostic testing in oncology, reproductive health, and rare diseases. In 2022, Sema4 acquired GeneDx, a leader in rare disease genomics, and subsequently transitioned its business to focus entirely on the GeneDx platform, eventually rebranding the entire company as GeneDx.